Skip to content

Advertisement

Sections

Page 1 of 35

  1. Content type: Research article

    Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...

    Authors: Marjolaine Debant, Miguel Burgos, Patrice Hemon, Paul Buscaglia, Tinhinane Fali, Sarra Melayah, Nelig Le Goux, Christophe Vandier, Marie Potier-Cartereau, Jacques-Olivier Pers, Adrian Tempescul, Christian Berthou, Cristina Bagacean, Olivier Mignen and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:111

    Published on:

  2. Content type: Research article

    The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8+, but not CD4+, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer ...

    Authors: Adam E. Snook, Trevor R. Baybutt, Bo Xiang, Tara S. Abraham, John C. Flickinger Jr, Terry Hyslop, Tingting Zhan, Walter K. Kraft, Takami Sato and Scott A. Waldman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:104

    Published on:

  3. Content type: Commentary

    Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fa...

    Authors: Albert D. Donnenberg, James D. Luketich, Rajeev Dhupar and Vera S. Donnenberg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:110

    Published on:

  4. Content type: Review

    Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administer...

    Authors: Kalijn F. Bol, Gerty Schreibelt, Katrin Rabold, Stefanie K. Wculek, Julia Katharina Schwarze, Andrzej Dzionek, Alvaro Teijeira, Lana E. Kandalaft, Pedro Romero, George Coukos, Bart Neyns, David Sancho, Ignacio Melero and I. Jolanda M. de Vries

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:109

    Published on:

  5. Content type: Review

    The activity of the commensal microbiota significantly impacts human health and has been linked to the development of many diseases, including cancer. Gnotobiotic animal models have shown that the microbiota h...

    Authors: Jessica Fessler, Vyara Matson and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:108

    Published on:

  6. Content type: Correction

    Following publication of the original article [1], the authors reported an error in their listed affiliations.

    Authors: Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Junsheng Ma, Roland L. Bassett Jr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E. Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:107

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:103

  7. Content type: Research article

    Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipient...

    Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:106

    Published on:

  8. Content type: Review

    The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising ...

    Authors: Jasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, Timothy P. Hickling, Ira A. Jacobs, Jeffrey Chou, Shahram Salek-Ardakani and Eugenia Kraynov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:105

    Published on:

  9. Content type: Research article

    The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high lev...

    Authors: Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, Khurum Khan, Louise J. Barber, Andrew Woolston, Georgia Spain, Katharina von Loga, Ben Challoner, Radhika Patel, Michael Ranes, Amanda Swain, Janet Thomas, Annette Bryant, Claire Saffery, Nicos Fotiadis…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:101

    Published on:

  10. Content type: Research article

    The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, h...

    Authors: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:103

    Published on:

  11. Content type: Research article

    To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.

    Authors: Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile and Vincenzo Esposito

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:102

    Published on:

  12. Content type: Research article

    How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast cancer is not well understood.

    Authors: Xiaotong Li, Sarah Warren, Vasiliki Pelekanou, Vikram Wali, Alessandra Cesano, Mingdong Liu, Patrick Danaher, Nathane Elliott, Zeina A. Nahleh, Daniel F. Hayes, Gabriel N. Hortobagyi, William E. Barlow, Christos Hatzis and Lajos Pusztai

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:88

    Published on:

  13. Content type: Research article

    The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies...

    Authors: Stefanie K. Wculek, Joaquín Amores-Iniesta, Ruth Conde-Garrosa, Sofía C. Khouili, Ignacio Melero and David Sancho

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:100

    Published on:

  14. Content type: Research article

    The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.

    Authors: Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:99

    Published on:

  15. Content type: Short report

    High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-reg...

    Authors: Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:98

    Published on:

  16. Content type: Case report

    Immune checkpoint inhibitors (ICIs) have provided more options in the treatment of lung cancer. However, ICIs can cause several unfavorable reactions generally referred to as immune-related adverse effects.

    Authors: Osamu Honjo, Terufumi Kubo, Fumiko Sugaya, Takahiro Nishizaka, Koji Kato, Yoshihiko Hirohashi, Hiroki Takahashi and Toshihiko Torigoe

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:97

    Published on:

  17. Content type: Commentary

    Two phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that overall survival (OS) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patient...

    Authors: Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, Raul E. Giglio, C. René Leemans, Tanguy Y. Seiwert and Denis Soulieres

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:96

    Published on:

  18. Content type: Research article

    Notch intercellular communication instructs tissue-specific T-cell development and function. In this study, we explored the roles of dendritic cell (DC)-expressed Notch ligands in the regulation of T-cell effe...

    Authors: Elena E. Tchekneva, Mounika U.L. Goruganthu, Roman V. Uzhachenko, Portia L. Thomas, Anneliese Antonucci, Irina Chekneva, Michael Koenig, Longzhu Piao, Anwari Akhter, Maria Teresa P. de Aquino, Parvathi Ranganathan, Nicholas Long, Thomas Magliery, Anna Valujskikh, Jason V. Evans, Rajeswara R. Arasada…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:95

    Published on:

  19. Content type: Correction

    Following publication of the original article [1], the author reported two errors in the authors affiliations:

    Authors: Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng, Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong and Ming-Hai Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:94

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:75

  20. Content type: Research article

    Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in pat...

    Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Xuemei Wang, Niharika Mallepally, Ellie Chen, Mehmet Altan, Robert S. Bresalier, Aline Charabaty, Ramona Dadu, Amir Jazaeri, Bret Lashner and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:93

    Published on:

  22. Content type: Short report

    The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For...

    Authors: Paolo A. Ascierto, Mariaelena Capone, Antonio M. Grimaldi, Domenico Mallardo, Ester Simeone, Gabriele Madonna, Heinrich Roder, Krista Meyer, Senait Asmellash, Carlos Oliveira, Joanna Roder and Julia Grigorieva

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:91

    Published on:

  23. Content type: Review

    Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, an...

    Authors: Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri and Aleix Prat

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:90

    Published on:

  24. Content type: Research article

    A male gender driven obesity paradox (improved survival for overweight/obese patients compared to normal weight) was recently shown in melanoma in the context of checkpoint inhibition (anti-PD-1/anti-CTLA4 mon...

    Authors: Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Jonathan D. Schoenfeld and Patrick A. Ott

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:89

    Published on:

  25. Content type: Research article

    Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burde...

    Authors: Biagio Ricciuti, Sasha Kravets, Suzanne E. Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl and Mark M. Awad

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:87

    Published on:

  26. Content type: Research article

    Permanence of front-line management of lung cancer by immunotherapies requires predictive companion diagnostics identifying immune-checkpoints at baseline, challenged by the size and heterogeneity of biopsy sp...

    Authors: Anne Monette, Derek Bergeron, Amira Ben Amor, Liliane Meunier, Christine Caron, Anne-Marie Mes-Masson, Nidhameddine Kchir, Kamel Hamzaoui, Igor Jurisica and Réjean Lapointe

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:86

    Published on:

  27. Content type: Review

    Quantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact prognosis and survival. The development of cancers in immunosuppressed patients has demonstrated the contribution o...

    Authors: Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay and Christophe Caux

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:85

    Published on:

  28. Content type: Research article

    Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms h...

    Authors: M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:84

    Published on:

  29. Content type: Short report

    Herein, we describe the use of systemic immunotherapy for both locally advanced and metastatic conjunctival melanoma. Current treatments for advanced conjunctival melanoma typically result in poor local contro...

    Authors: Paul T. Finger and Anna C. Pavlick

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:83

    Published on:

  30. Content type: Research article

    Immunotherapy targeting PD-1/PD-L1 fails to induce clinical responses in most patients with solid cancers. N-803, formerly ALT-803, is an IL-15 superagonist mutant and dimeric IL-15RαSushi-Fc fusion protein co...

    Authors: Karin M. Knudson, Kristin C. Hicks, Sarah Alter, Jeffrey Schlom and Sofia R. Gameiro

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:82

    Published on:

  31. Content type: Short report

    Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if ad...

    Authors: Rosa Nguyen, Huiyun Wu, Stanley Pounds, Hiroto Inaba, Raul C. Ribeiro, David Cullins, Barbara Rooney, Teresa Bell, Norman J. Lacayo, Kenneth Heym, Barbara Degar, Deborah Schiff, William E. Janssen, Brandon Triplett, Ching-Hon Pui, Wing Leung…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:81

    Published on:

  32. Content type: Research article

    Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab,...

    Authors: Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold and Jeffrey S. Weber

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:80

    Published on:

  33. Content type: Research article

    Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical managem...

    Authors: Madelyn Espinosa-Cotton, Samuel N. Rodman III, Kathleen A. Ross, Isaac J. Jensen, Kenley Sangodeyi-Miller, Ayana J. McLaren, Rachel A. Dahl, Katherine N. Gibson-Corley, Adam T. Koch, Yang-Xin Fu, Vladimir P. Badovinac, Douglas Laux, Balaji Narasimhan and Andrean L. Simons

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:79

    Published on:

  34. Content type: Research article

    Low availability of oxygen in tumors contributes to the hostility of the tumor microenvironment toward the immune system. However, the dynamic relationship between local oxygen levels and the immune surveillan...

    Authors: Mateusz Rytelewski, Karine Haryutyunan, Felix Nwajei, Meenakshi Shanmugasundaram, Patrick Wspanialy, M. Anna Zal, Chao-Hsien Chen, Mirna El Khatib, Shane Plunkett, Sergei A. Vinogradov, Marina Konopleva and Tomasz Zal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:78

    Published on:

  35. Content type: Research article

    Intrahepatic cholangiocarcinoma (ICC) is a highly mortal malignancy with limited therapeutic options. Immunotherapies targeting PD-1/PD-L1 pathway represent a promising treatment for ICC. However, PD-L1 expres...

    Authors: Chu-Yu Jing, Yi-Peng Fu, Yong Yi, Mei-Xia Zhang, Su-Su Zheng, Jin-Long Huang, Wei Gan, Xin Xu, Jia-Jia Lin, Juan Zhang, Shuang-Jian Qiu and Bo-Heng Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:77

    Published on:

  37. Content type: Research article

    Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are u...

    Authors: Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng, Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong and Ming-Hai Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:75

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:94

  38. Content type: Research article

    Immunotherapies still fail to benefit colorectal cancer (CRC) patients. Relevant functional assays aimed at studying these failures and the efficacy of cancer immunotherapy in human are scarce. 3D tumor cultur...

    Authors: Tristan Courau, Julie Bonnereau, Justine Chicoteau, Hugo Bottois, Romain Remark, Laura Assante Miranda, Antoine Toubert, Mathieu Blery, Thomas Aparicio, Matthieu Allez and Lionel Le Bourhis

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:74

    Published on:

  39. Content type: Correction

    .

    Authors: Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang and Hans J. Hammers

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:73

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:109

  40. Content type: Research article

    Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce...

    Authors: Derek L. Clouthier, Scott C. Lien, S. Y. Cindy Yang, Linh T. Nguyen, Venkata S. K. Manem, Diana Gray, Michael Ryczko, Albiruni R. A. Razak, Jeremy Lewin, Stephanie Lheureux, Ilaria Colombo, Philippe L. Bedard, David Cescon, Anna Spreafico, Marcus O. Butler, Aaron R. Hansen…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:72

    Published on:

  41. Content type: Short report

    Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sough...

    Authors: Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J. Philip, Jo Ann Hsu, Nazli Dizman, Ulka Vaishampayan, Tanya Dorff and Sumanta Kumar Pal

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:71

    Published on:

  42. Content type: Research article

    The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as ...

    Authors: Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:70

    Published on:

  43. Content type: Research article

    γ9δ2T cells, which express Vγ9 and Vδ2 chains of the T cell receptor (TCR), mediate cancer immune surveillance by sensing early metabolic changes in malignant leukemic blast and not their healthy hematopoietic...

    Authors: Inez Johanna, Trudy Straetemans, Sabine Heijhuurs, Tineke Aarts-Riemens, Håkan Norell, Laura Bongiovanni, Alain de Bruin, Zsolt Sebestyen and Jürgen Kuball

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:69

    Published on:

  44. Content type: Research article

    Tumor progression is accompanied by dramatic remodeling of the surrounding extracellular matrix leading to the formation of a tumor-specific ECM, which is often more collagen-rich and of increased stiffness. T...

    Authors: Dorota E. Kuczek, Anne Mette H. Larsen, Marie-Louise Thorseth, Marco Carretta, Adrija Kalvisa, Majken S. Siersbæk, Ana Micaela C. Simões, Anne Roslind, Lars H. Engelholm, Elfriede Noessner, Marco Donia, Inge Marie Svane, Per thor Straten, Lars Grøntved and Daniel H. Madsen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:68

    Published on:

  45. Content type: Research article

    Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular imm...

    Authors: Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski and Alfred Zippelius

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:67

    Published on:

  46. Content type: Case report

    Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivol...

    Authors: Craig Labbate, Ken Hatogai, Ryan Werntz, Walter M. Stadler, Gary D. Steinberg, Scott Eggener and Randy F. Sweis

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:66

    Published on:

  47. Content type: Research article

    Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune c...

    Authors: Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N. Gettinger, Roy S. Herbst, David L. Rimm and Kurt A. Schalper

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:65

    Published on:

  48. Content type: Commentary

    Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-...

    Authors: Anna Wilkins, Fiona McDonald, Kevin Harrington and Alan Melcher

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:64

    Published on:

  49. Content type: Correction

    .

    Authors: Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:63

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:40

  50. Content type: Case report

    Balancing the potential for durable remissions with autoimmune-like toxicities is a key clinical challenge in the use of immune checkpoint inhibitors (ICI). Certain toxicities are associated with an increased ...

    Authors: Suthee Rapisuwon, Benjamin Izar, Cory Batenchuk, Alexandre Avila, Shaolin Mei, Peter Sorger, Jerry M. Parks, Sarah J. Cooper, David Wagner, Jay C. Zeck, Aline J. Charabaty and Michael B. Atkins

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:61

    Published on:

Submit manuscript

Follow

Annual Journal Metrics

Advertisement

Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426

Contact us